Board MemberPhD, FCIC, FRSC
Vice-President, Research and Innovation at the University of Windsor
K. W. Michael Siu has had extensive experience on administration in academia. He is currently Vice-President, Research and Innovation at the University of Windsor (December 2012 – present). Prior to his current post, Siu served at York University as Associate Vice-President Research, Science & Technology (2005 – 2011); Founding Director, Centre for Research in Mass Spectrometry (2000 – 2012); and Member, Board of Governors, 2004 – 2006). In addition, he has served / is serving in various leadership, administration and governance positions in Canadian and international research organizations, including Chair, Ontario Council on University Research (2017 – 2018); Executive, Board of Directors, Southern Ontario Super Computing Innovation Platform (SOSCIP) (2016 – present); President, Canadian Society for Mass Spectrometry (2009 – 2012); Chair, Board of Directors, Canadian National Proteomics Network (2008 – 2012); and Member, Board of Directors, Human Proteome Organization (2010 – 2012).
His academic experience and accomplishments are equally extensive. He is currently Professor of Chemistry and Biochemistry at the University of Windsor. At York University, he was Distinguished Research Professor (2007 – 2014) and NSERC / AB SCIEX Senior Industrial Research Chair in Analytical Mass Spectrometry (1998 – 2012). Siu has published > 270 papers (Google Scholar, August 17, 2018: h-index, 60; i10-index, 211; total citations, 11,443; # papers cited ≥ 100 times, 27) and given > 480 presentations, of which > 50% are in the invited, keynote and plenary category. He is a Fellow of the Chemical Institute of Canada and the Royal Society of Canada. Siu has received multiple awards, as well as funding and grants from many agencies and organizations totalling > $ 22 million. The oral cancer biomarkers that Siu and his collaborators and identified have now been commercialized and offered as a prognostic test (Straticyte: www.proteocyteai.com) for oral premalignant lesions that may transform into cancers.